Cooper Financial Group Sells 8,270 Shares of Exelixis, Inc. $EXEL

Key Points

• Cooper Financial Group reduced its stake in Exelixis, Inc. by 37.7% in Q2, selling 8,270 shares and holding 13,663 shares valued at $602,000.
• Various institutional investors have modified their stakes in Exelixis, with 85.27% of the stock now owned by institutional investors.
• Exelixis reported a quarterly EPS of $0.75, beating analyst estimates of $0.63, but its revenue fell by 10.8% compared to the previous year.

Cooper Financial Group cut its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 37.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,663 shares of the biotechnology company's stock after selling 8,270 shares during the period. Cooper Financial Group's holdings in Exelixis were worth $602,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of EXEL. Hemington Wealth Management raised its stake in shares of Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 522 shares during the last quarter. Byrne Asset Management LLC grew its holdings in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 400 shares during the period. Family Legacy Financial Solutions LLC acquired a new stake in Exelixis during the 2nd quarter worth $33,000. Bartlett & CO. Wealth Management LLC acquired a new stake in Exelixis during the 1st quarter worth $37,000. Finally, Costello Asset Management INC acquired a new stake in Exelixis during the 1st quarter worth $39,000. 85.27% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. JMP Securities restated a "market outperform" rating and set a $50.00 price objective on shares of Exelixis in a report on Tuesday, July 29th. Royal Bank Of Canada decreased their price objective on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating for the company in a report on Tuesday, July 29th. William Blair restated an "outperform" rating on shares of Exelixis in a report on Tuesday, July 29th. Stifel Nicolaus boosted their price objective on shares of Exelixis from $38.00 to $41.00 and gave the company a "hold" rating in a report on Tuesday, July 29th. Finally, UBS Group set a $38.00 price target on shares of Exelixis and gave the company a "neutral" rating in a report on Wednesday, July 30th. Fourteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $44.42.

Exelixis Price Performance

Shares of EXEL opened at $41.20 on Thursday. Exelixis, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $49.62. The firm has a market capitalization of $11.09 billion, a PE ratio of 19.81, a PEG ratio of 0.85 and a beta of 0.38. The company's 50-day moving average is $38.75 and its 200-day moving average is $39.80.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. During the same period last year, the firm earned $0.84 earnings per share. Exelixis's revenue for the quarter was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.